Close

BIO Expresses Strong Support for TRID Improvement Act

Feb 12 2018
Legislation provides critical regulatory relief to small, pre-revenue emerging companies Washington, D.C. (February 12, 2018)— The Biotechnology Innovation Organization (BIO) announced its strong support today for H.R. 3978, the TRID Improvement Act. The bill includes a provision known as the Fostering Innovation Act, which offers much needed regulatory relief to small biotechnology firms. 

BIO Releases Report on State of Innovation for Pain and Addiction Therapeutics

Feb 12 2018
Report highlights the need to stimulate innovation to battle the opioid epidemic Washington, DC (February 12, 2018) – Today, the Biotechnology Innovation Organization (BIO) released a new report, The State of Innovation in Highly Prevalent Chronic Diseases: Pain and Addiction Therapeutics. While many promising treatment approaches are in development, lower investment and pipeline breadth in pain and addiction relative to other disease areas with high societal health burdens demonstrates the need for incentivizing more research and clinical development in these areas.

BIO Applauds Introduction of the Vaccine Access Improvement Act

Feb 9 2018
Washington, DC (February 9, 2018) – – The Biotechnology Innovation Organization (BIO) applauds Reps. Mike Kelly (R-PA) and Brian Higgins (D-NY) for introducing H.R. 4993, the Vaccine Access Improvement Act, which would promote timely access to new first-in-class childhood and maternal vaccines. The legislation would update the tax code to ensure new first-in-class vaccines are promptly covered under the National Vaccine Injury Compensation Program (VICP).  

South Dakota Governor Daugaard Signs Bill Facilitating Patient Access to Interchangeable Biologic Medicines

Feb 9 2018

Washington, D.C. (February 09, 2018) – The Biotechnology Innovation Organization (BIO) and the South Dakota Biotech Association...

BIO Statement on Medicare Part D Changes in Budget Deal

Feb 8 2018
Washington, DC (February 8, 2018) – BIO President and CEO Jim Greenwood issued the following statement today regarding proposed changes to the Medicare Part D program in the announced budget deal.

BIO Statement on U.S. Falling to 12th Ranking of International Patent System Strength

Feb 8 2018
The steady decline of America as an innovation-supporting economy is due to an unbalanced patent challenge system.  

BIO’s Statement on the Confirmation of Andrei Iancu to Lead the U.S. Patent and Trademark Office

Feb 5 2018

Washington, D.C. (February 5, 2018) – The following statement may be attributed to BIO President & CEO James Greenwood:

...

BIO Applauds USDA-FDA Agreement to Improve Coordination

Jan 30 2018
Washington, D.C. (January 30, 2018) – The Biotechnology Innovation Organization (BIO) is applauding a new agreement announced by the U.S. Department of Agriculture (USDA) and the Food and Drug Administration (FDA) to enhance coordination between the two agencies on program areas such as biotechnology.

BIO Congratulates Alex Azar on Confirmation as Secretary of Health and Human Services

Jan 24 2018
BIO Congratulates Alex Azar on Confirmation as Secretary of Health and Human Services   Washington, DC (January 24, 2018) – Biotechnology Innovation Organization (BIO) President and CEO Jim Greenwood issued the following statement regarding the confirmation of Alex Azar as United States Secretary of Health and Human Services (HHS):

BIO Releases First Report in a Series on the State of Innovation in Highly Prevalent Chronic Diseases

Jan 18 2018
First-of-its-kind report highlights the need to stimulate development efforts for depression therapeutics.   Washington, DC (January 18, 2018) – Today, the Biotechnology Innovation Organization (BIO) released a new report, The State of Innovation in Highly Prevalent Chronic Diseases: Depression Therapeutics, the first in a series on the current funding and R&D land scape for drugs to treat highly prevalent, chronic diseases.